Previous 10 | Next 10 |
home / stock / aavxf / aavxf news
Abivax (AAVXF) said that ABX464, its candidate for ulcerative colitis ("UC") with a new mechanism of action, demonstrated reductions in multiple disease activity measurements in a phase 2b study.As a result, the French biotech will move ahead with a phase 3 trial, which is expected to start b...
Abivax SA (AAVXF) has completed induction treatment in the last patient in a phase 2b trial of ABX464 for ulcerative colitis.Top-line data from the induction phase is expected in May.Top-line data from ABX464 after 48 weeks as a maintenance therapy is expected in Q1 2022.A phase 3 study is ex...
ABIVAX Société Anonyme (AAVXF): FY Operating loss of €38.0M.Cash of €29.3M.Press Release For further details see: ABIVAX Société Anonyme reports FY results
Abivax ([[AAVXF]] -30.1%) has announced that it will end the miR-AGE phase 2b/3 clinical trial in high-risk Covid-19 patients on recommendations of an independent Data Safety and Monitoring Board (“DSMB”) that cited lack of efficacy.In a randomized, double-blind, and p...
Prometheus Biosciences has filed to raise $125 million in a U.S IPO. The firm is developing treatments for inflammatory bowel disease conditions. RXDX is in Phase 1 safety trials for its lead candidate for the treatment of ulcerative colitis and Crohn's disease. For further ...
French biotech Abivax SA ( OTCPK:AAVXF ) announces that Brazil's Health Regulatory Agency has signed off on its Phase 2/3 clinical trial, MiR-AGE , evaluating lead candidate ABX464 for the treatment of inflammation and prevention of acute respiratory failure in COVID-19 patients. More n...
Abivax ( OTCPK:AAVXF ) received a €5M in non-dilutive financing , with 12 months maturity at 0.25% interest, from Société Générale in the form of a loan guaranteed by the French state. This is beside the €36M non-dilutive funding in May 2020 granted by Bpif...
ABIVAX Société Anonyme ( OTCPK:AAVXF ): 1H Net loss of €14.17M. More news on: ABIVAX Société Anonyme, Earnings news and commentary, , Read more ...
Abivax SA (AAVXF) Q4 2018 Earnings Conference Call March 15, 2019 9:00 AM ET Company Participants Hartmut Ehrlich - Chief Executive Officer Didier Blondel - Chief Financial Officer Jean-Marc Steens - Chief Medical Officer Conference Call Participants Dylan van Haaften - NIB...
Abivax ( OTCPK:AAVXF ) announces that the Data Safety Monitoring Board (DSMB) has recommended continuation of its ongoing 12-month extension study, ABX464-102, continuing its completed placebo-controlled Phase 2a induction trial, ABX464-101. More news on: Abivax SA, Healthcare stocks new...
News, Short Squeeze, Breakout and More Instantly...
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025 Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with ...
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabi...
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients...